Autinorm syrup: no trials of the product, and its folate is not the one the research used

Sample size: Zero participants have been studied on Autinorm. The comparison evidence: a systematic review and meta-analysis of 21 leucovorin studies, including four placebo-controlled trials
Demographics: Autistic children across the leucovorin studies; no Autinorm population exists to describe
Key outcome: No study of Autinorm exists. The review it leans on states that 'd,l-Leucovorin is only form of folate that has been used to treat CFD except for one case report using 5-MTHF' — and 5-MTHF is what Autinorm contains.
Methodology: A product-claim check. The composition of Autinorm was taken from pharmacy listings and the manufacturer's own promotional material, then compared against a 2021 systematic review and meta-analysis of cerebral folate deficiency and leucovorin in autism, and against current clinical guidance from the American Academy of Pediatrics and the Child Neurology Society.
Researchers: Daniel A. Rossignol, Richard E. Frye
Institutes: Rossignol Medical Center, Barrow Neurological Institute at Phoenix Children's Hospital, American Academy of Pediatrics, Child Neurology Society

Limitations:

• Absence of published trials is not proof a product does nothing — it means nobody has checked
• The product's own label and recommended daily dosing were read from retail listings, not from a regulatory dossier
• The leucovorin evidence base itself is contested: the Child Neurology Society notes data integrity concerns in several studies
• The meta-analysis authors are the principal investigators of much of the leucovorin research they reviewed
• Individual children with a confirmed diagnosis may respond differently to anything discussed here

• A search for clinical evidence on Autinorm returns no trials, no published studies and no results in autism — only pharmacy listings, social media promotion and parent forum discussion.
• Autinorm's active ingredient is Quatrefolic, a methylfolate (5-MTHF) salt, at 240 mcg per 5 ml. The autism research it echoes used d,l-leucovorin (folinic acid), a different molecule available only on prescription.
• That distinction is the heart of the matter. Cerebral folate deficiency often happens because antibodies block the folate receptor alpha — the very transporter that carries 5-MTHF into the brain. Leucovorin is used because it can take a second route in, through the reduced folate carrier.
• The 2021 meta-analysis states directly that folinic acid is the only form of folate used to treat cerebral folate deficiency, with the sole exception of one case report using 5-MTHF.
• Dose is the other gap. The leucovorin studies used 2 mg/kg/day up to 50 mg daily, with even the 'moderate dose' arm below 5 mg/day. A 240 mcg serving is a fraction of that.
• Even for leucovorin, the Child Neurology Society states there is no adequately powered, pre-registered placebo-controlled trial establishing efficacy for core autism symptoms, that folate receptor antibody testing is not recommended as a basis for clinical decisions, and that it should not be prescribed as standard care for autism.

• If Autinorm was recommended to you as evidence-based for autism, the evidence being invoked is for a different medicine that a doctor has to prescribe and monitor.
• Cerebral folate deficiency is a real diagnosis, but it is diagnosed through genetic testing and, definitively, by measuring folate in spinal fluid — not by trying a syrup and watching.
• If folate has genuinely come up for your child, the conversation to have is with a paediatric neurologist about proper testing, not with a pharmacy counter.
• The American Academy of Pediatrics notes that reduced folates can shift brain chemistry in ways that may be positive, neutral or negative depending on the individual child, which is exactly why leucovorin is prescription-only.
• Folate is not automatically harmless at any dose in any form: the review notes high doses of plain folic acid may block the folate receptor and could in principle worsen cerebral folate deficiency.

• Nothing here says Autinorm is dangerous. It says it is untested, and that the research used to sell it studied something else.
• This is a claim check against the published literature, not a laboratory analysis of the product.
• The leucovorin field is genuinely unsettled and moving. Promising early findings exist alongside serious methodological criticism from paediatric neurology bodies.
• A child who seems better after starting any supplement may be responding to time, therapy, expectation or ordinary development — which is precisely what placebo-controlled trials exist to separate out.
• Tell your child's doctor about any over-the-counter product you are giving, including this one, so it can be seen alongside everything else.

• Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis — Rossignol & Frye, 2021, Journal of Personalized Medicine 11(11):1141
• Leucovorin Use in Autism and Cerebral Folate Deficiency: FAQs for Pediatricians — American Academy of Pediatrics
• CNS Position Statement on Leucovorin Use in Autism and Related Disorders — Child Neurology Society
• Leucovorin: Is there science behind that? — Association for Science in Autism Treatment
• Autinorm 200ml Syrup — product composition listing (Quatrefolic 240 mcg/5 ml, Kepler Healthcare) — MedPlusMart product listing

• L-carnosine for autistic children: an early promise the later trials did not confirm — General
• What risperidone 0.5 mg (sold as Sizodone) does — and does not do — for autistic children — Behaviour
• Understanding Sensory Issues and Humming in Autistic Children: What Caregivers Need to Know — Sensory

---

This summary was prepared by the Curioler research agent. It is not medical advice. Always consult a qualified professional before making decisions about your child's care.